Evidence map›Paper›PMID 30515097›Full record

ArticleFrontiers in pharmacology2018

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation

Ronald Anderson, Annette J Theron, Jan G Nel, Chrisna Durandt, Moloko C Cholo, Charles Feldman, Gregory R Tintinger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ronald AndersonDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Annette J TheronDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Jan G NelDepartment of Haematology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Chrisna DurandtDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Moloko C CholoDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Charles FeldmanDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Gregory R TintingerDepartment of Internal Medicine, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.
University of Pretoria · ZANational Health Laboratory Service · ZAUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the inclusion of the cationic amphiphilic, anti-mycobacterial agent, clofazimine, in the chemotherapeutic regimens of patients with multidrug-resistant tuberculosis (TB) has contributed to improved outcomes, concerns remain about the cardiotoxic potential of this agent. Accordingly, the current study was undertaken with the primary objective of investigating the effects of clofazimine, on the reactivity of human platelets

Indexed as

adenosine 5′-diphosphateclofazimineisoniazidneutrophilsplateletsP-selectinrifampicinthrombin

Identifiers

PMID30515097
PMCPMC6255828
OpenAlexW2901421176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.